CD29 (Integrin beta 1) Monoclonal Antibody (TS2/16), eBioscience™, Invitrogen™

Description

• Description: The TS2/16 monoclonal antibody reacts with human CD29, also known as integrin beta 1, an approximately 130 kDa single-pass transmembrane glycoprotein
• CD29 complexes with one of nine integrin alpha subunits to form the very late antigen (VLA) subfamily of adhesion molecules
• Integrin heterodimers containing CD29 are involved in cell-cell and cell-matrix adhesion
• CD29 is expressed broadly on lymphocytes and monocytes, with lower levels of expression on granulocytes
• The TS2/16 antibody has been found to possess activating activity for beta 1 integrins
• Applications Reported: This TS2/16 antibody has been reported for use in flow cytometric analysis, immunoprecipitation, and immunohistochemical staining
• Applications Tested: This TS2/16 antibody has been tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at less than or equal to 0.25 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• ITGB1 (Integrin Subunit Beta 1, beta1 integrin subunit, GPIIa, CD29) is a 110 kDa cell surface glycoprotein that is widely expressed by a variety of cells including all leucocytes
• ITGB1 forms non-covalently linked heterodimers with at least 6 different alpha chains (alpha1-alpha6, CDa-f) determining the binding properties of beta1 (VLA) integrins
• ITGB1 is a cell adhesion molecule appearing on platelets, as the common Beta subunit of the very late activation antigen (VLA), and as a component of various protein complexes binding to extracellular matrix proteins
• Decreased expression of ITGB1 correlates with acquiring multidrug resistance of tumor cells in the presence of anti-tumor drug
• ITGB1 is up-regulated in leukocytes during emigration and extravascular migration and appear to be critically involved in regulating the immune cell trafficking from blood to tissue
• Further, ITGB1 also regulates tissue damage and disease symptoms related to inflammatory bowel disease
• Through an ITGB1-dependent mechanism, fibronectin and type I collagen enhance cytokine secretion of human airway smooth muscle in response to IL-1beta
• More than 8 beta subunits with numerous splice variant isoforms have been identified in mammals
• There are two major forms of integrin beta1: beta1A and beta1D, which differ in 13 amino acids
• The distribution pattern in adult tissues for integrin beta types are mutually exclusive
• Beta1A is present in all tissues, except cardiac and skeletal muscle which express the beta1D variant.